CTLA4 Fusion Protein Autoantigen Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 1 diabetes mellitus lack effective methods to halt or slow autoimmune β-cell destruction, leading to the progression of the disease, and there is a need for therapies that can prolong the onset of the disease or preserve residual β-cell function.
Innovation Solution
Administration of a fusion protein composition comprising a T-cell co-stimulation antagonist like CTLA4 and a Type 1 diabetes autoantigen, such as preproinsulin, GAD 65, or insulin B-chain, to modulate the immune response and prevent autoimmune β-cell destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunomodulatory agents or antigen-based treatments are used, then β-cell function preservation is improved, but the ability to halt autoimmune destruction is insufficient
Solution Approach 1:
The patent combines a T-cell co-stimulation antagonist (CTLA4 fusion protein) with a Type 1 diabetes autoantigen into a single pharmaceutical composition. This merging of two distinct therapeutic mechanisms - immune modulation through CTLA4 and antigen-specific tolerance through autoantigen - creates a synergistic effect that simultaneously preserves β-cell function and halts autoimmune destruction, resolving the contradiction between these two outcomes.
2Ease of operation
If insulin therapy is administered, then blood glucose control is improved, but residual β-cell function is not preserved
Solution Approach 1:
The patent applies preliminary action by administering the CTLA4 fusion protein and autoantigen combination therapy at the time of diabetes diagnosis, before complete β-cell destruction occurs. This early intervention modulates the ongoing autoimmune response and preserves remaining β-cell function, allowing patients to maintain endogenous insulin production longer and potentially reduce or eliminate insulin therapy requirements.
3Reliability
If autoimmune response is activated, then immune system function is improved, but β-cell destruction is accelerated
Solution Approach 1:
The patent converts the harmful autoimmune response into a beneficial therapeutic effect by using the autoantigen to redirect the immune response. The CTLA4 fusion protein modulates T-cell co-stimulation to suppress pathogenic autoimmunity, while the autoantigen induces antigen-specific tolerance. This transforms the harmful autoimmune attack on β-cells into a protective immune modulation that preserves β-cell function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively delays the onset of diabetes by preserving residual β-cell function, as measured by C-peptide secretion, and reduces the need for insulin therapy, offering a longer remission period and delaying diabetes-related complications.
Implementation Method 1
The T-cell co-stimulation antagonist binds a B7 (CD80/86) antigen expressed on B cells and/or on antigen presenting cells (APCs)
Implementation Method 2
Reintroduction of autoantigen, such as insulin B-chain, in incomplete Freund's adjuvant (IFA), has also been contemplated for the treatment or delayed progression of Type 1 diabetes
Implementation Method 3
Reintroduction of autoantigen, such as insulin B-chain, in incomplete Freund's adjuvant (IFA)
Data Source
AI summary
A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.